TOI
Oncology Institute, Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$2.4M | first quarter call | — |
| Specialty pharmacy revenue run-rate | $27M | second-half 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TOI
this stock
Oncology Institute, Inc.
|
$579.90M | +62.9% | +27.8% | — | 6.7% |
|
HCA
HCA Healthcare, Inc.
|
$93.86B | -9.2% | +7.1% | 14.6 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.09B | -13.0% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.99B | +5.1% | -2.3% | 10.9 | 4.7% |
|
DVA
Davita Inc.
|
$15.04B | +106.2% | +6.5% | 21.9 | 7.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TOI | +3.6% | +19.1% | +50.7% | +6.8% | +62.9% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +2.7% | +17.7% | +43.1% | +6.7% | +53.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.